Overview

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is designed to determine the adrenal effects of the investigational formulation of 122-0551 and characterize the steady state pharmacokinetics of the formulation.
Phase:
Phase 2
Details
Lead Sponsor:
Therapeutics, Inc.